TY - JOUR
T1 - Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS
AU - Vermersch, Patrick
AU - Oh, Jiwon
AU - Cascione, Mark
AU - Oreja-Guevara, Celia
AU - Gobbi, Claudio
AU - Travis, Lori H.
AU - Myhr, Kjell Morten
AU - Coyle, Patricia K.
N1 - Funding Information:
Development of this manuscript was supported by Sanofi .
Funding Information:
Patrick Vermersch: Honoraria, consulting fees from Almirall, Bayer, Biogen, Celgene, Genzyme, Sanofi, GSK, Merck Serono, Novartis, Servier, and Teva; research support from Bayer, Biogen, Genzyme, Sanofi, and Merck Serono.Jiwon Oh: Consulting or speaking fees from Biogen Idec, EMD Serono, Genzyme, Novartis, Roche, and Celgene; and research support from Biogen Idec, Roche, and Sanofi.Mark Cascione: Funding/honoraria for research, consultation, and speaker's bureau participation from Alexion, Bayer HealthCare, Biogen, Celgene, EMD Serono, Genentech, Genzyme/Sanofi, Novartis, and Roche.Celia Oreja-Guevara: Honoraria for speaking and/or consultancy from Biogen, Sanofi-Genzyme, Merck, Roche, Teva, and Novartis.Claudio Gobbi: The employer of CG received grants from Almirall, Bayer Schering, Biogen, Genzyme, Merck Serono, Novartis, Roche, and Teva within the past 5 years.Lori Hendin Travis: Consulting fees from Acorda, Biogen, EMD Serono, Genzyme, Novartis, Pfizer, Teva, and Mallinckrodt; research support from Biogen, EMD Serono, and Genzyme.Kjell-Morten Myhr: Received unrestricted research grants to his institution; scientific advisory board, and speaker honoraria from Almirall, Biogen, Genzyme, Merck, Novartis, Roche, and Teva; and has participated in clinical trials organized by Biogen, Merck, Novartis, and Roche.Patricia K. Coyle: Consulting fees from Accordant, Alexion, Bayer, Biogen Idec, Celgene, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Mylan, Novartis, Serono, and TG Therapeutics; research support from Actelion, Alkermes, Corrona LLD, Genentech/Roche, MedDay, NINDS, Novartis, and PCORI.Development of this manuscript was supported by Sanofi.Medical writing and editorial support, under the direction of the authors, was provided by Orapim Tulyathan, PhD, Chloe Malloy, MSc, Deborah Brown, PhD, and Rachael Cazaly for Onyx (Knutsford, UK), funded by Sanofi, according to Good Publication Practice guidelines (Link). The manuscript was reviewed for scientific accuracy by Darren P. Baker, PhD, Jonathan Valenzano, PharmD, and Karyn Liu, PhD, of Sanofi. The authors were responsible for all content and editorial decisions, and received no honoraria related to the development of this publication.
Funding Information:
Lori Hendin Travis: Consulting fees from Acorda, Biogen , EMD Serono, Genzyme , Novartis , Pfizer , Teva , and Mallinckrodt; research support from Biogen , EMD Serono, and Genzyme .
Publisher Copyright:
© 2020 The Authors
PY - 2020/8
Y1 - 2020/8
N2 - Multiple sclerosis (MS) is a chronic, immune-mediated, inflammatory disease affecting the white and gray matter of the central nervous system. Several disease modifying therapies (DMTs) have been shown to significantly reduce relapse rates, slow disability worsening, and modify the overall disease course of MS. Decision-making when initiating a DMT should be shared between the patient and physician. Important factors such as prognostic indicators, safety, patient preferences, adherence, and convenience should also be considered. Treatment guidelines recommend switching a DMT when a patient experiences breakthrough disease activity, but also for patients who experience adverse events. Compared with injectable therapies, oral DMTs are often associated with increased treatment adherence and patient satisfaction, due to a less burdensome route of administration and greater tolerability. This review will summarize the available scientific evidence for injectable DMTs and the oral DMT teriflunomide, including considerations for both treatment-naïve patients initiating a DMT and patients switching from an injectable DMT.
AB - Multiple sclerosis (MS) is a chronic, immune-mediated, inflammatory disease affecting the white and gray matter of the central nervous system. Several disease modifying therapies (DMTs) have been shown to significantly reduce relapse rates, slow disability worsening, and modify the overall disease course of MS. Decision-making when initiating a DMT should be shared between the patient and physician. Important factors such as prognostic indicators, safety, patient preferences, adherence, and convenience should also be considered. Treatment guidelines recommend switching a DMT when a patient experiences breakthrough disease activity, but also for patients who experience adverse events. Compared with injectable therapies, oral DMTs are often associated with increased treatment adherence and patient satisfaction, due to a less burdensome route of administration and greater tolerability. This review will summarize the available scientific evidence for injectable DMTs and the oral DMT teriflunomide, including considerations for both treatment-naïve patients initiating a DMT and patients switching from an injectable DMT.
KW - Disease modifying therapies
KW - Injectable DMTs
KW - Multiple sclerosis
KW - Switching
KW - Teriflunomide
UR - http://www.scopus.com/inward/record.url?scp=85085294709&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085294709&partnerID=8YFLogxK
U2 - 10.1016/j.msard.2020.102158
DO - 10.1016/j.msard.2020.102158
M3 - Review article
C2 - 32470857
AN - SCOPUS:85085294709
SN - 2211-0348
VL - 43
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
M1 - 102158
ER -